Ibuprofen API Market

Ibuprofen API Market Highlights

The global ibuprofen API market is expected to cross a value of USD 798.4 million by the end of 2032. The market was valued at USD 641.7 million in 2023 and is expected to expand at a CAGR of 3.2% between 2024-2032.

• Over the mid-term, the growing demand for nonsteroidal anti-inflammatory drugs (NSAID) is the primary factor anticipated to drive the global ibuprofen API market.
• The growing concern for the adverse effects associated with ibuprofen drug is a major factor to challenge the market growth.
• The Asia Pacific ibuprofen API market is projected to dominate the global market.

Ibuprofen API Market Outlook

Ibuprofen API is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used to relieve pain, reduce inflammation, and lower fever. Ibuprofen API, which stands for Ibuprofen Active Pharmaceutical Ingredient, refers to the pure, pharmacologically active substance of ibuprofen that serves as the primary therapeutic component in various pharmaceutical formulations.

Our analysts at KD Market Insights have found that the growing demand for nonsteroidal anti-inflammatory drugs (NSAID), backed by the rising prevalence of pain disorders, is one of the primary factors expected to drive the growth of the market in the coming years. Over the years, there has been an increase in prevalence of pain-related conditions, such as arthritis, migraines, and menstrual cramps, thereby raising the need for pain management drugs, such as ibuprofen. According to the statistics by the World Health Organization (WHO), about 528 million people globally were living with osteoarthritis in 2019. This was recorded to be an increase of 113% since 1990. BASF SE, Lonza Group Ltd., and Teva Pharmaceutical Industries Ltd. are some of the significant parties in the global market for ibuprofen API.

                  Get More Insights on This Report - Request Free Sample PDF

Ibuprofen API Market Drivers – Analyst’s Observation

According to the analysts at KD Market Insights, some key growth drivers for the global ibuprofen API market are:

• Growing Demand for Generic Drugs: In several developing regions worldwide, the demand for generic drugs has witnessed multifold growth. Our researchers have estimated that the demand for generic drugs worldwide would cross USD 110 billion in the next 2 years. The generic versions of ibuprofen are usually more affordable than its branded alternatives. As a result, the accessibility to these generic drugs to a broader population is usually very high, creating numerous opportunities for market growth.
• Expanding Ageing Population Worldwide: The ageing population are prone to different kind of chronic conditions, such as osteoarthritis and rheumatoid arthritis, which often requires pain management. Hence, as their population increases globally, the demand for pain management drugs is expected to increase.

Which Probable Factors Could Hamper the Growing Ibuprofen API Market Trend?

As per our KD Market Insights analysis, some of the challenges expected to limit the global market growth of ibuprofen API are:

• Higher Competition from Generic Drug Manufacturers: The ibuprofen API market faces significant competition from generic manufacturers who produce lower-cost versions of ibuprofen. This intense competition can lead to price erosion and reduced profit margins for companies manufacturing ibuprofen API, thereby restraining market growth.
• Concern for Adverse Effects Associated with Ibuprofen Drug: Despite its widespread use, ibuprofen is associated with certain risks and adverse effects, such as gastrointestinal bleeding, cardiovascular events, and kidney damage, particularly with long-term or high-dose use. Such a factor is therefore expected to limit the market growth in the coming years.

How is the Global Ibuprofen API Market Segmented?

Our experts at KD Market Insights have segmented the global ibuprofen API market as:

What are the Probable Factors Influencing the Asia Pacific Ibuprofen API Market Forecast?

The Asia Pacific ibuprofen API market is majorly driven by the growing healthcare expenditure in the region, followed by the growing incidences of chronic diseases and the expanding pharmaceutical industry. The Asia Pacific region is experiencing rapid economic growth, leading to higher healthcare spending. As more people gain access to healthcare services and medications, the demand for ibuprofen API is expected to rise. Alternatively, the prevalence of chronic diseases such as arthritis, musculoskeletal disorders, and headaches is increasing, thereby raising the need for pain management drugs. Additionally, with the rise in demand for generic medications globally, the production and export of ibuprofen API from the Asia Pacific region is also expected to increase, and in turn, contribute to the market growth.

As per our analysts at KD Market Insights, the following five players lead the Asia Pacific ibuprofen API market growth:

• Aurobindo Pharma Limited
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• Cipla Limited

Which Key Players Top the Global Ibuprofen API Market Share?

As per our analysts at KD Market Insights, the competitive landscape of global ibuprofen API market facilitates our readers in identifying their closest competitors. The manufacturers who are associated with ibuprofen API market are raising their focus on expanding their presence, as well as their market share. The market has also been witnessing an upward movement in the number of collaborations between research institutions and key players, aimed at introducing advanced technologies and innovation of new products. Here is a list of the key players who top the global ibuprofen API market share:

• BASF SE
• Lonza Group Ltd.
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Pfizer Inc.
• Sanofi
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Sun Pharmaceutical Industries Ltd.
• Novartis International AG
• Mylan N.V.
• Lupin Limited

What are the Recent Developments Observed in the Ibuprofen API Market?

Over the years, the experts at KD Market Insights have been observing the recent developments associated with global ibuprofen API market trends. Our expert’s market forecast analysis has recorded the market players adopting plentiful of key strategies including new product launches, mergers & acquisitions, and collaborations.

For instance, Azelis stated that in association with Clariant, it has entered into a new distribution deal, wherein, the customers of Azelis in Austria, Germany, and Switzerland have access to the APIs of Clariant.

Further, Lonza shared that it has completed the construction of a laboratory at its API manufacturing facility in Nansha, China.